SimConverse
Founded 2020 Β· 16 employees on LinkedIn Β· 2 known investors
SimConverse is an AI simulation platform for clinical and healthcare education, offering photorealistic avatars that let learners practice patient conversations and receive personalized, rubric-based feedback and analytics. It serves universities and healthcare educators across fields such as nursing, medicine, pharmacy, optometry, and surgery, with tools for curriculum setup, cohort management, and accreditation reporting.
Also known as Dymaxion Technologies Pty Ltd
Investors Β· 2
Company profile
researched Aug 2026SimConverse operates an AI simulation platform for healthcare and clinical education. Its technology generates simulated patients, colleagues, family members and casualties that learners speak with in verbal consultations, replacing or supplementing the human 'simulated/standardised patient' actors traditionally used in role-play training. The platform presents photorealistic avatars and supports multi-modal assessment covering spoken communication, selection and sequencing of clinical investigations and actions, and written clinical documentation.
Activities are structured around a five-stage instructional model the company describes as pedagogy-first: preparation (activating prior knowledge), conversation (practice in a psychologically safe environment), documentation (clinical note-writing), feedback (personalized, criterion-level comments tied to rubrics and quoting the learner's own performance), and reflection. Educators can configure visuals, voices, characters, actions, investigations, rubrics and written artifacts, deploy activities to large cohorts with automatic cohort assignment, permissions and reminders, and review rubric heatmaps from institution level down to individual criteria, with one-click accreditation exports.
For institutional buyers the company offers curriculum mapping, AI training, SSO and LTI integration and accreditation exports delivered by its own team, and cites SOC 2 Type 2 certification alongside HIPAA, FERPA, UK GDPR and Privacy Act compliance, with data and infrastructure hosted in data centres local to the customer. Disciplines covered in published studies and deployments include optometry, pharmacy, nursing, medicine and surgery.
Founding story
Co-founders Aiden Roberts and Will Pamment met while studying medicine at university. They first pitched investors on Dymaxion Technologies, a data integration layer, then pivoted to build SimConverse to digitise healthcare education and communication-skills training using generative AI. Roberts, the CEO, frames the problem around communication breakdowns being implicated in a large share of medical errors and patient harm.
Business model
Sells its simulation platform to institutional customers β universities, hospitals, health networks and government health services β positioning itself as a consolidated replacement for multiple experiential-learning tools, with enterprise integration and support services delivered by its own team. The company describes delivering human-actor-equivalent training results at software prices, with unlimited usage and scale.
Sold to institutions as a platform, with the company describing unlimited usage at unlimited scale and pricing positioned at software cost levels versus the cost of employing human simulation actors.
Traction
Reported as used by over 50 institutions at the time of its 2023 seed round, and its research page cites effectiveness demonstrated across more than 12,000 learners in a 2024 multi-site cross-sectional analysis. The homepage lists institutional customers with start dates ranging from 2021 to 2025 and references five years of proven results.
Latest developments
Published research and case studies dated 2025 include a randomized controlled study at Aston University's School of Optometry (Ting & Wolffsohn, Clinical and Experimental Optometry) finding no significant difference from human actors, a Villanova University College of Nursing quasi-experimental study reporting a 1.65 standard deviation improvement in communication skills and PHQ-A depression screening accuracy rising from 56% to 82%, a mixed-methods study of 200 students at the University of Nottingham School of Pharmacy reporting 88.9% overall satisfaction, and a qualitative acceptability study at Aston University Medical School reporting 98.9% acceptability. A single-blinded randomized controlled trial at the University of Auckland Department of Surgery run from 2023 to 2025 reported significantly more distinction grades in the SimConverse cohort than in the control group.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
Positions itself against human simulated-patient actors β the previous gold standard β and against general-purpose AI chatbots, citing a randomized study in which its outcomes were statistically indistinguishable from human actors (p = 0.86) while general-purpose AI was rated significantly worse (p < 0.001). Its investor described existing simulation tools, including mannequins, text-based platforms and VR, as limited for communication training.
Claims to be the only AI education platform meeting the full set of procurement and cybersecurity requirements of large organizations, government and military, through jurisdiction-local hosting, SOC 2 Type 2 certification and HIPAA/FERPA/UK GDPR/Privacy Act compliance; and to use purpose-built clinical models instead of outsourced general-purpose LLMs. It also emphasises a modular content approach letting educators tailor scenarios to specific curricula, and a design derived from established learning theory.
Technology
Uses proprietary generative AI models trained on curated clinical communication datasets built over roughly half a decade, rather than general-purpose LLMs such as ChatGPT, Claude or Gemini; the company states this yields clinically accurate and consistent responses without hallucination. The platform combines photorealistic avatars, real-time spoken conversation, complex reasoning, and automated rubric-based assessment of speech, clinical actions and written documentation, with SSO/LTI integration and customer-local data hosting.
Go-to-market
Works directly with universities, hospitals and government health networks; the website markets via demo bookings and leans on independent peer-reviewed research and educator testimonials from institutions such as Aston University, Villanova University, the University of Auckland, the University of Nottingham, Western Sydney University and Westmead Hospital. Seed funding was earmarked for customer expansion in the US, UK and Australia.
Healthcare education institutions and providers: university schools of medicine, nursing, pharmacy, optometry and surgery; hospitals; government health networks; and, per the company, large organizations, government and military buyers with procurement and cybersecurity requirements. Named early customers include Queensland Health, NHS Lothian, the University of Canberra, the University of Liverpool and King's College London.
Geography
Headquartered in Sydney, Australia, with operations and customers across Australia, the United Kingdom and the United States; seed funding was directed at growth in those three markets. Research partners and cited users also include institutions in New Zealand.
History
Reported as founded in 2020 by Aiden Roberts and Will Pamment, following a pivot from their earlier venture Dymaxion Technologies. The corporate entity behind the company is recorded as Dymaxion Technologies Pty Ltd. In March 2023 the company announced a A$1.5 million seed round led by Folklore Ventures with Artesian participating, at which point it was operating in Australia, the UK and the US with more than 50 institutions using the platform. Its website lists customers onboarded each year from 2021 through 2025 and peer-reviewed and institutional studies published between 2023 and 2025.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 1
launches, deals, and filingsSeed round of A$1.5 million led by Folklore Ventures with participation from Artesian, to be used to expand the customer base in the US, UK and Australia.
$1.5M source β
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- SimConversesimconverse.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does SimConverse do?
- AI patient-simulation platform used by universities and health services to train clinical communication skills.
- Who are SimConverse's investors?
- SimConverse's investors include Artesian, Folklore Ventures.